Blog | Nammi Therapeutics

Nov 8, 20241 min read

Nammi Therapeutics, Inc. Announces First Patient Dosed with QXL138AM in a Phase 1 Study Evaluating Advanced Solid Tumors and Multiple Myeloma

Nammi Therapeutics, Inc., a clinical stage immuno-oncology company with a diverse pipeline created with the Masked-Immunocytokine (MIC)...

Aug 6, 20241 min read

Nammi Therapeutics announces a $1M investment commitment by the Myeloma Investment Fund in a $30M Series B financing round prior to the...

Feb 6, 20231 min read

Nammi Therapeutics was featured in the Los Angeles Business Journal. The article featured an interview with David Stover, President and...

Jan 6, 20231 min read

Amgen and BioLabs LA at The Lundquist Institute today announced that Nammi Therapeutics has been awarded the third Amgen Golden Ticker in...

Dec 15, 20221 min read

The governing Board of the California Institute for Regenerative Medicine (CIRM) funded a Phase 3 clinical trial to support the...

Jun 15, 20221 min read

FDA has granted orphan drug designation (OOD) to Nammi Therapeutic's lead program, QXL138AM, for the treatment of Pancreatic Cancer. QXL...

Jun 12, 20221 min read

FDA has granted orphan drug designation (OOD) to Nammi Therapeutic's lead program, QXL138AM, for the treatment of multiple myeloma. QXL...

Apr 9, 20212 min read

LOS ANGELES, April 9, 2021 /PRNewswire/ -- Nammi Therapeutics, Inc. (Nammi), an LA- based immunotherapy company, announces its first two...

May 17, 20194 min read

Veteran drug developer David Stover decided to start his own firm the day Astellas Pharma Inc. shuttered its Santa Monica-based Agensys...